Zhejiang Starry Pharmaceutical

Taizhou, China Founded: 1997 • Age: 29 yrs
APIs and intermediates for contrast media and Fluoroquinolones are manufactured.

About Zhejiang Starry Pharmaceutical

Zhejiang Starry Pharmaceutical is a company based in Taizhou (China) founded in 1997.. Zhejiang Starry Pharmaceutical has completed 1 acquisition, including Imax Diagnostic. Zhejiang Starry Pharmaceutical operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Apicore, among others.

  • Headquarter Taizhou, China
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
    $319.21 M (USD)
    7.05
    as on Dec 31, 2024
  • Net Profit
    $-6.73 M (USD)
    -211
    as on Dec 31, 2024
  • EBITDA
    $37.96 M (USD)
    -14.7
    as on Dec 31, 2024
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Zhejiang Starry Pharmaceutical

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by Zhejiang Starry Pharmaceutical

Zhejiang Starry Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Imax Diagnostic. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
APIs are manufactured and imaging services are provided.
2011
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Zhejiang Starry Pharmaceutical

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Zhejiang Starry Pharmaceutical Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Zhejiang Starry Pharmaceutical

Zhejiang Starry Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Apicore, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical and biotechnology company
domain founded_year HQ Location
Contract development, manufacturing, and analytical services for APIs are offered.
domain founded_year HQ Location
APIs and drug products are developed and valorized in pharmaceuticals.
domain founded_year HQ Location
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
domain founded_year HQ Location
APIs are manufactured and custom synthesis services are provided.
domain founded_year HQ Location
APIs are developed and manufactured for therapeutic areas.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Zhejiang Starry Pharmaceutical

Frequently Asked Questions about Zhejiang Starry Pharmaceutical

When was Zhejiang Starry Pharmaceutical founded?

Zhejiang Starry Pharmaceutical was founded in 1997.

Where is Zhejiang Starry Pharmaceutical located?

Zhejiang Starry Pharmaceutical is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.

Who is the current CEO of Zhejiang Starry Pharmaceutical?

Hu Jinsheng is the current CEO of Zhejiang Starry Pharmaceutical.

What is the annual revenue of Zhejiang Starry Pharmaceutical?

Annual revenue of Zhejiang Starry Pharmaceutical is $319.21M as on Dec 31, 2024.

What does Zhejiang Starry Pharmaceutical do?

Zhejiang Starry Pharmaceutical was founded in 1997 and is based in Taizhou, China. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) and intermediates are produced for X-CT non-ionic contrast media, MRI contrast media, and Fluoroquinolones. Products include Iohexol, Ioversol, Iopamidol, Iodixanol, Iopromide, Iomeprol, Gadobenate, and related compounds. Manufacturing occurs primarily for global supply chains in diagnostic imaging and antimicrobial applications.

Who are the top competitors of Zhejiang Starry Pharmaceutical?

Zhejiang Starry Pharmaceutical's top competitors include Laurus Labs, Symbiotec and Beijing Biostar Technologies.

How many acquisitions has Zhejiang Starry Pharmaceutical made?

Zhejiang Starry Pharmaceutical has made 1 acquisition, including Imax Diagnostic.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available